MidFirst Bank Invests $8.82 Million in Amgen Inc. $AMGN

Posted by on Jun 19th, 2026

MidFirst Bank purchased a new stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 26,954 shares of the medical research company’s stock, valued at approximately $8,822,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in AMGN. Robeco Institutional Asset Management B.V. grew its position in Amgen by 10.0% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company’s stock worth $157,584,000 after acquiring an additional 43,884 shares in the last quarter. Curtis Advisory Group LLC acquired a new stake in shares of Amgen in the 4th quarter valued at $1,669,000. Adell Harriman & Carpenter Inc. boosted its holdings in Amgen by 7.9% in the fourth quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company’s stock worth $7,204,000 after purchasing an additional 1,609 shares in the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new position in Amgen during the fourth quarter worth $22,441,000. Finally, Sigma Planning Corp raised its holdings in Amgen by 24.0% during the fourth quarter. Sigma Planning Corp now owns 17,992 shares of the medical research company’s stock valued at $5,889,000 after buying an additional 3,488 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Price Performance

NASDAQ:AMGN opened at $337.60 on Friday. The stock has a market cap of $182.21 billion, a P/E ratio of 23.49, a PEG ratio of 3.43 and a beta of 0.42. Amgen Inc. has a one year low of $267.83 and a one year high of $391.29. The company has a fifty day moving average price of $340.96 and a 200 day moving average price of $345.81. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01.

Amgen (NASDAQ:AMGN – Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The company had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. During the same period last year, the business posted $4.90 EPS. The business’s quarterly revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Analysts anticipate that Amgen Inc. will post 22.38 earnings per share for the current year.

Insider Buying and Selling at Amgen

In related news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the sale, the senior vice president directly owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.85% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on AMGN. Morgan Stanley raised their price objective on Amgen from $332.00 to $340.00 and gave the company an “equal weight” rating in a research note on Tuesday, June 9th. Jefferies Financial Group started coverage on shares of Amgen in a research note on Tuesday, March 10th. They issued a “hold” rating and a $350.00 price objective for the company. Argus lowered their target price on shares of Amgen from $400.00 to $375.00 and set a “buy” rating on the stock in a research note on Wednesday, May 20th. Barclays initiated coverage on shares of Amgen in a research report on Friday, February 20th. They set an “equal weight” rating and a $350.00 target price for the company. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Amgen in a research report on Friday, June 12th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, fifteen have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $354.42.

Check Out Our Latest Analysis on Amgen

Amgen Profile

(Free Report)

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Read More

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.